UNSPSC 51461600: Combination herbs/alternative therapies

This classification denotes combination drugs and preparations that consist in whole or part of roots, leaves, seeds, bark, or other plant parts, and which possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, derived from herbaceous plants, or those which have leaves and stems, and which therefore bear the name HERBS. Typical combination herb/alternative therapy constituents are cinnamon, glucosamine, iodine, soy, zinc citrate.

UNSPSC 51461600 Combination herbs/alternative therapies is a Class code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing agreements and authorized wholesale channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body identified in recent activity. Work under this code involves manufacturers submitting detailed product specifications—including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations—to establish supply contracts across participating state and local government facilities. Vendors must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and carry comprehensive insurance coverage including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Pricing structures must accommodate flat price, net price formats (NF30, NF60, NF90), or WAC-minus models, with evaluation weighted heavily toward price competitiveness (75 percent) and compliance with administrative requirements.

The most recent representative opportunity is MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, establishing multiple awards effective July 1, 2026 through June 30, 2028. The RFP covers participating state and local government facilities across Minnesota and Oregon. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs, with performance penalties of $200 to $1,500 per violation for issues such as late reporting, missed onboarding timelines, or improper class-of-trade denials. The code shows limited recent activity; the single MMCAP solicitation dominates current visibility under this classification.